Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03189914 · ClinicalTrials.gov registry record · Phase 1
RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Processa Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT03189914 is a Phase 1 study that has completed, run by Processa Pharmaceuticals. The registered enrollment target is 46 participants.
The verdict
NCT03189914, a Phase 1 study, has completed, sponsored by Processa Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. After completion of the Phase 1 portion, a Phase 2a study will be conducted using a 2 stage, open-label design, of RX 3117 and Abraxane® in combination to treat subjects with metastatic pancreatic cancer as first line therapy.
Interventions
- DRUG RX-3117
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2017-10-02 |
| Est. Completion | 2019-11-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03189914
The ClinicalTrials.gov registry entry for NCT03189914 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Processa Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RX-3117 is the first listed.
NCT03189914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03189914 about?
NCT03189914 is a clinical study titled "RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer". This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. After completion of the Phase 1 portion, a Phase 2a study will be conducted us...
What is the current status of trial NCT03189914?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2017-10-02. Estimated completion is 2019-11-21.
What interventions are being tested in trial NCT03189914?
The interventions under investigation include: RX-3117 (DRUG).
Who is sponsoring clinical trial NCT03189914?
This trial is sponsored by Processa Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.